Brazil’s Health Regulator Suspends Trial Of China’ Sinovac Coronavirus Vaccine, Citing Severe Adverse Event Among Participant

Wall Street Journal: Brazil Suspends Trials of China’s Sinovac Coronavirus Vaccine
“Brazil’s health regulator Anvisa said Monday it has suspended clinical trials of China’s Sinovac coronavirus vaccine, long expected to be one of the first to be approved in the country, following a ‘severe adverse event.’ Anvisa said late Monday that the event occurred on Oct. 29, without giving further information or an explanation of why it took more than a week to communicate the problem. Brazil’s Butantan Institute, the research center in São Paulo that has been developing the vaccine in partnership with Sinovac, a private Chinese company, said that it was surprised by Anvisa’s decision. It said it was investigating and would hold a press conference Tuesday morning…” (Pearson, 11/10).

Additional coverage of the trial’s suspension is available from AP, Bloomberg, Financial Times, and Reuters.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.